Alzheimer's disease

Insights from the AD/PD meeting, continued fallout from the FDA layoffs, hope for GLP-1 drugs in Alzheimer’s disease, and more led industry news this week.

A landmark UTI drug approval, new hope for the amyloid hypothesis in Alzheimer’s disease, a brewing vaccine study controversy, and more led the news this week.

DDN editors break down a surprising connection between microplastics and antimicrobial resistance, vitamin D for multiple sclerosis, obesity drugs updates, and more news from this week.

New gene therapies in clinical trials seek to treat Alzheimer’s disease and heal the brain with a dose of helpful genetic material.

By watching brain organoids develop, researchers observed surprising abnormalities caused by mutations in a gene related to early-onset Alzheimer’s disease.

Young blood rejuvenates aging organs in rodents. Researchers are studying the potential to use young blood-based treatments in aging humans too.

Activating specific neurons using light helped scientists establish a causal link between improved sleep and diminished signs of Alzheimer’s disease in mice.

Slight modifications to glycoproteins reveal critical insights into disease onset, state, and progression, making them a wellspring for biomarker discovery. 

A small molecule called ALGERNON2 improved health outcomes in mouse models of neurodegenerative diseases by activating antioxidant pathways in astrocytes.

A dementia-associated tau mutation promotes unusual clustering of Fyn, a protein important for learning and memory.